Compare DERM & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DERM | TNXP |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 199.7M |
| IPO Year | 2021 | 2008 |
| Metric | DERM | TNXP |
|---|---|---|
| Price | $6.24 | $9.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.67 | N/A |
| AVG Volume (30 Days) | 157.2K | ★ 484.8K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.72 | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,858,000.00 | $13,107,000.00 |
| Revenue This Year | $39.72 | $558.11 |
| Revenue Next Year | $63.24 | $38.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 10.20 | ★ 29.85 |
| 52 Week Low | $4.31 | $9.81 |
| 52 Week High | $9.56 | $69.65 |
| Indicator | DERM | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 37.21 |
| Support Level | $5.80 | N/A |
| Resistance Level | $6.59 | $13.18 |
| Average True Range (ATR) | 0.37 | 0.88 |
| MACD | -0.13 | -0.21 |
| Stochastic Oscillator | 17.93 | 3.49 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.